{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:50:42Z","timestamp":1789041042112,"version":"build-2803163510"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1001\/jamapediatrics.2018.2530","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T20:05:10Z","timestamp":1539201910000},"page":"1161","source":"Crossref","is-referenced-by-count":81,"title":["Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia"],"prefix":"10.1001","volume":"172","author":[{"given":"Melanie D.","family":"Whittington","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Brett","family":"McQueen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Ollendorf","sequence":"additional","affiliation":[{"name":"The Institute for Clinical and Economic Review, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun M.","family":"Kumar","sequence":"additional","affiliation":[{"name":"The Institute for Clinical and Economic Review, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Chapman","sequence":"additional","affiliation":[{"name":"The Institute for Clinical and Economic Review, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Tice","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Pearson","sequence":"additional","affiliation":[{"name":"The Institute for Clinical and Economic Review, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"poi180057r1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.v64.2","article-title":"Childhood and adolescent cancer statistics, 2014.","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"poi180057r2","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1002\/cncr.v123.S24","article-title":"Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: findings from the CONCORD-2 study.","volume":"123","author":"Tai","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"poi180057r4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"issue":"2","key":"poi180057r5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"poi180057r6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1634\/theoncologist.6-3-247","article-title":"High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma.","volume":"6","author":"Mink","year":"2001","journal-title":"Oncologist"},{"key":"poi180057r12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"poi180057r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol Assess"},{"issue":"4","key":"poi180057r15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/pbc.v48:4","article-title":"Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada.","volume":"48","author":"MacArthur","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"poi180057r16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal.","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"issue":"12","key":"poi180057r17","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"poi180057r18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/pbc.v62.5","article-title":"Using nonrandomized studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia.","volume":"62","author":"Kelly","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"poi180057r20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis.","volume":"97","author":"Sung","year":"2003","journal-title":"Cancer"},{"key":"poi180057r21","article-title":"IBM Micromedex.","year":"2018","journal-title":"Redbook"},{"issue":"6","key":"poi180057r24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/01.CCM.0000164543.14619.00","article-title":"Daily cost of an intensive care unit day: the contribution of mechanical ventilation.","volume":"33","author":"Dasta","year":"2005","journal-title":"Crit Care Med"},{"issue":"5","key":"poi180057r25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamapediatrics.2018.0049","article-title":"Considerations for cost-effectiveness analysis of curative pediatric therapies.","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"5","key":"poi180057r26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jval.2013.02.014","article-title":"NICE\u2019s selective application of differential discounting: ambiguous, inconsistent, and unjustified.","volume":"17","author":"O\u2019Mahony","year":"2014","journal-title":"Value Health"},{"issue":"10","key":"poi180057r27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"poi180057r29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"poi180057r30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jval.2017.12.018","article-title":"Affordability challenges to value-based pricing: mass diseases, orphan diseases, and cures.","volume":"21","author":"Danzon","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"poi180057r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/14737167.2015.990887","article-title":"Financing cures in the United States.","volume":"15","author":"Basu","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"poi180057r32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jval.2018.01.011","article-title":"Affordability of new technologies: the next frontier.","volume":"21","author":"Towse","year":"2018","journal-title":"Value Health"},{"key":"poi180057r11","author":"US Food and Drug Administration"},{"key":"poi180057r19","year":"2017"},{"key":"poi180057r22","volume-title":"Pediatric Cancer Hospitalizations, 2009. HCUP Statistical brief #132","author":"Price","year":"2012"},{"key":"poi180057r28","volume-title":"Cost-Effectiveness Analysis of Kymriah for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States","author":"Hao","year":"2017"},{"key":"poi180057r3","unstructured":"American Cancer Society. Treatment of children with acute lymphocytic leukemia (ALL). https:\/\/www.cancer.org\/cancer\/leukemia-in-children\/treating\/children-with-all.html. Accessed May 2, 2018."},{"key":"poi180057r7","unstructured":"FDA.gov. FDA approval brings first gene therapy to the United States. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm574058.htm. Published August 30, 2017. Accessed September 1, 2017."},{"key":"poi180057r8","unstructured":"Institute for Clinical and Economic Review. CAR-T therapies: final evidence report. https:\/\/icer-review.org\/material\/car-t-final-report\/. Accessed on March 23, 2018."},{"key":"poi180057r9","unstructured":"HagenT. Novartis sets a price of $475,000 for CAR T-cell therapy. https:\/\/www.onclive.com\/web-exclusives\/novartis-sets-a-price-of-475000-for-car-tcell-therapy. Published August 30, 2017. Accessed September 1, 2017."},{"key":"poi180057r10","unstructured":"Novartis. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice. https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019. Published August 30, 2017. Accessed August 16, 2018."},{"key":"poi180057r13","unstructured":"HuangM, LatimerN, ZhangY, MukhopadhyayP, OuwensM, BriggsA. Estimating the long-term outcomes associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. Value & Outcomes Spotlight. January\/February 2018. https:\/\/www.ispor.org\/publications\/journals\/value-outcomes-spotlight\/abstract\/january-february-2018\/estimating-the-long-term-outcomes-associated-with-immuno-oncology-therapies-challenges-and-approaches-for-overall-survival-extrapolations. Accessed June 28, 2018."},{"key":"poi180057r23","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule Search. https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/license-agreement.aspx. Accessed March 2, 2018."}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2704489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T16:02:41Z","timestamp":1543852961000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpedi.jamanetwork.com\/article.aspx?doi=10.1001\/jamapediatrics.2018.2530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2018.2530","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}